Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease

Pediatric Blood and Cancer

Volumn 47, Issue 7, 2006, Pages 894-900

  Kratovil, Tonya ^a   Bulas, Dorothy ^b,c   Driscoll, M Catherine ^b,c   Speller Brown, Barbara ^b   McCarter, Robert ^b,c   Minniti, Caterina P ^b,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Hydroxyurea; Sickle cell disease; Stroke; Transcranial doppler

Indexed keywords

HYDROXYUREA;

ADOLESCENT; ARTICLE; BLOOD FLOW VELOCITY; BLOOD TOXICITY; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOPPLER ECHOGRAPHY; FEMALE; FOLLOW UP; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MALE; NEPHROTOXICITY; PREDICTION; PRIORITY JOURNAL; RETICULOCYTE COUNT; RISK ASSESSMENT; SCHOOL CHILD; SICKLE CELL ANEMIA; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT DURATION; VELOCITY;

ADOLESCENT; ANEMIA, SICKLE CELL; BLOOD FLOW VELOCITY; CHILD; CHILD, PRESCHOOL; FEMALE; HEMOGLOBINS; HUMANS; HYDROXYUREA; LEUKOCYTE COUNT; MALE; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 33750032587     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20819     Document Type: Article

References (25)

1. Jayabose S, Tugal O, Sandoval C, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996;129:560-565.
2. Scott JP, Hillery CA, Brown ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996;128:820-828.
3. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS Study, a phase I/II Trial. Blood 1999;94:1550-1554.
4. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-termo hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103:2039-2045.
5. Wang WC, Wynn LW, Rogers AR, et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 2001;139:790-796.
6. Hoppe C, Vichinsky E, Quirolo K, et al. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. J Pediatr Hematol Oncol 2000;22:330-334.
7. Ferster A, Tahiri C, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97:3628-3632.
8. de Montalembert M, Belloy M, Bernaudin F, et al. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. J Pediatri Hematol Oncol 1997;19:313-318.
9. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. JAMA 2003;289:1645-1651.
10. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999;94:3022-3026.
11. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: The Belgian experience. Blood 2005;105:2685-2690.
12. Ohene-Frempong K. Stroke in sickle cell disease: Demographic, clinical and therapeutic considerations. Semin Hematol 1991;28:213-219.
13. Balkaran B, Char G, Morris JS, et al. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992;120:360-366.
14. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 1998;91:288-294.
15. Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. NEJM 1992;326:605-610.
16. Adams RJ, McKie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol 1997;42:699-704.
17. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. NEJM 1998;339:5-11.
18. Bulas DI, Jones A, Siebert JJ, et al. Transcranial Doppler (TCD) screening for stroke prevention in sickle cell anemia: Pitfalls in technique variation. Pediatr Radiol 2000;30:733-738.
19. Fitzmaurice GM, Laird NM, Ware J. Applied Longitudinal Analysis. Hoboken, NJ: John Wiley & Sons; 2004, 1-18.
20. StatCorp, Stata Statistical Software: Release 8.0, College Station, TX, Stata Corporation 2003; 326-356.
21. Zimmerman SA, Schultz WH, Davis JS, et al. Hydroxyurea therapy lowers transcranial doppler velocities in children with sickle cell anemia. Natl Sickle Cell Dis Conf Program 2002. (Abstract).
22. Adams RJ, Brambilla DJ, Granger S, et al. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood 2004;103:3689-3694.
23. Olivieri N, Brambilla D, McKie V, et al. Changes in cerebral blood flow velocities during chronic transfusion therapy to prevent stroke in sickle cell disease. Blood 2000;96:486a (Abstract).
24. Venketasubramanian N, Prohovnik I, Hurlet A, et al. Middle cerebral artery velocity changes during transfusion in sickle cell anemia. Stroke 1994;25:2153-2158.
25. Davis CE. The effect of regression to the mean in epidemiologic and clinical studies. Am J Epidemiol 1976;493-498.